InspireMD Inc. announced the publication of results from its C-GUARDIANS pivotal trial in the Journal of the American College of Cardiology (JACC). The study evaluated the safety and efficacy of the CGuard® Prime Carotid Stent System, which uses MicroNet™ technology, for carotid artery stenting in patients with asymptomatic carotid stenosis. The trial demonstrated a 30-day DSMI rate of 0.95% and a one-year ipsilateral stroke rate of 1.93%, the lowest reported in pivotal carotid stenting studies, including in a cohort with 25% symptomatic patients. The results have already been published and are available for review. CGuard® Prime is FDA PMA-approved for the treatment of carotid artery stenosis in the United States.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InspireMD Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001158707-en) on January 12, 2026, and is solely responsible for the information contained therein.